The efficacy of eprinomectin in an extended-release injection (ERI) formulation was evaluated in cattle harbouring induced infestations of Sarcoptes scabiei var. bovis (sarcoptic mange) in three studies conducted in Germany (two studies) and Austria (one study). A total of 44 cattle were included in the studies, 12 in one study and 16 in each of the other two studies. Approximately eight weeks following initial induced infestation, cattle in each study were formed into replicates of two animals each on the basis of pre-treatment bodyweights. Within replicates the animals were randomly allocated to one of two treatments: ERI vehicle (control) or Eprinomectin 5% (w/v) ERI (1.0 mg eprinomectin/kg). Treatments were administered at 1 mL/50 kg bodyweight by subcutaneous injection in front of the shoulder once on day 0. The number of live mites in skin scrapings was determined prior to treatment and at weekly intervals for eight weeks after treatment. Severity of skin lesions was evaluated and scored when skin scrapings were taken. In all studies, animals were weighed before infestation and again prior to and at 56 days after treatment.
Introduction
Sarcoptic mange is caused by infestation with mites of the species Sarcoptes scabiei. Based on adaptation to several host species, varieties have been accepted and the mite infesting cattle is named S. scabiei var. bovis (syn. S. bovis).
Sarcoptes mites burrow into the epidermis creating tunnels of up to 1 cm in length, in which they feed and reproduce. Their burrowing and feeding activities cause inflammation and severe pruritus, loss of hair, and excoriation, marked thickening, and proliferation of the epidermal layer of the skin.
Sarcoptic mange is highly contagious and transferred by close physical contact between animals. It tends to spread all over the body of cattle and may result in considerable economic losses. The intense irritation and the alteration of the normal skin morphology and function lead to poor weight gain and lower feed conversion efficacy, impairing the value of the carcass, and they cause severe defects of the hide which result in substantial devaluation of the leather. In addition, sarcoptic mange causes disturbances in normal behaviour with increasing levels of rubbing and scratching and a reduction in time spent lying down (Rehbein et al., 2003a (Rehbein et al., , 2003b .
Eprinomectin belongs to the avermectin subclass of the macrocyclic lactone parasiticides (Shoop and Soll, 2002) . It has demonstrated excellent nematocidal, insecticidal and miticidal activity against a wide range of internal and external parasites of cattle (Shoop et al., 1996; Gogolewski et al., 1997a Gogolewski et al., , 1997b Holste et al., 1997 Holste et al., , 1998 Pitt et al., 1997; Williams et al., 1997; Yazwinski et al., 1997; Campbell et al., 2001; Rehbein et al., 2005) . Activity of eprinomectin in a 0.5% formulation administered topically at 1 mL/10 kg bodyweight (0.5 mg eprinomectin/kg) against Sarcoptes mite infestations was reported in several controlled studies and under field conditions (Barth et al., 1997; Thompson et al., 1997; Watson and Forbes, 2000; Rehbein et al., 2003a) .
In order to extend the persistent activity of eprinomectin with regard to endoparasites, an injectable formulation has been developed which releases the active in concentrations to provide effective control of nematode infections in cattle for up to 150 days (Soll et al., 2013) . In this extended-release injection (ERI) formulation, eprinomectin is released from a matrix formed with poly(d,l-lactide-co-glycolic)acid (PLGA). PLGA is known as a safe and effective biodegradable material which has been used as a drug delivery system for extended release applications of various pharmaceutical compounds, including ivermectin (Lewis, 1990; Miller et al., 1999; Clark et al., 2004; Winzenburg et al., 2004) .
The objective of the studies reported here was to evaluate the therapeutic efficacy of Eprinomectin ERI formulation against infestations with S. scabiei var. bovis (sarcoptic mange) on cattle.
Materials and methods
A total of three controlled studies were conducted according to similar protocols, two in Germany and one in Austria. The studies were designed and conducted to comply with the regulatory requirements of both the FDA/CVM and the European Medicines Agency/Committee for Medicinal Products for Veterinary Use, and according to relevant guidelines for Good Clinical Practices (GCPs) and for establishing the efficacy of acaricides against mange mites on ruminants (Vercruysse et al., 2006) .
The studies were performed as blinded studies, i.e., all personnel involved in collecting data were masked to the treatment assignment of the animals.
Experimental animals
A total of 44 (28 male and 16 female) healthy, ruminating Braunvieh (Brown Swiss) or Fleckvieh (Simmental) cattle, weighing 149-248 kg prior to treatment (day-1), and aged approximately five to seven months, were included in three studies conducted in Germany (studies 1 and 2) and in Austria (study 3). The animal descriptions and details are presented in Table 1 . Animals had not been treated previously with an avermectin or milbemycin product and were free of Sarcoptes mite infestation (as determined by thorough body inspection and/or examination of skin scrapings prior to initial mite infestation).
In all studies, cattle were held indoors under conventional conditions including ambient temperature and lighting. They were individually housed, tethered and stanchioned so as to prevent self-grooming and physical contact between animals. The animals were maintained on forage-based diets in each of the studies as per local practice (hay combined with either corn cobs or corn silage). Drinking water was supplied by automatic waterers.
Animals were handled and treated with due regard for their welfare and in compliance with Merial Institutional Animal Care and Use Committee (IACUC) approvals, as well as according to applicable local regulations, and requirements of the local IACUC.
Infestations
In each study, the animals were infested experimentally at the withers with the following numbers of S. scabiei var. bovis mites: study 1, ∼7300 and ∼6400 mites applied on study days −56 and −49, respectively; study 2, ∼6800 and ∼4200 mites applied on study days −56 and −50, respectively; study 3, ∼1600 and ∼2800 mites applied on study days −57 and −48, respectively. The Sarcoptes strain used for experimental infestation of cattle in the German studies was isolated from a naturally-infested cow in Germany and had been passaged continuously on cattle before being used for infestation of the study animals. The Sarcoptes mites used to infest the cattle in the Austrian study were collected directly from a naturally-infested Braunvieh cow purchased at a local livestock market in Austria shortly before the commencement of the study in late autumn.
Experimental design
A randomized block design based on pre-treatment bodyweight was used in each study with the individual animal being the experimental unit. Six (study 1) or eight replicates of two cattle each (studies 2 and 3) were formed sequentially based on decreasing pre-treatment (day −1) bodyweight. Within replicates, animals were allocated randomly to treatment: one to the control (vehicle-treated) group and one to the Eprinomectin ERI group. Six or eight blocks of stanchions were formed. Assignments of replicates to blocks and of animals within blocks to stanchion were done at random.
Treatments, vehicle (formulation that consisted of the excipients of the Eprinomectin ERI) or Eprinomectin ERI (eprinomectin 5% in a PLGA-based formulation) at 1.0 mg eprinomectin/kg, were administered at 1 mL/50 kg (1 mL/110 lb) bodyweight once (day 0) by subcutaneous injection in front of the shoulder using commercial disposable syringes and needles. All cattle were observed hourly for four or five hours post-treatment and thereafter once daily throughout the studies for health problems or adverse drug events.
Animals were weighed prior to initial infestation (day −56 for studies 1 and 2, day −58 for study 3), prior to treatment (day −1) for allocation and dose calculation, and at study end (day 56). 
Mite counts and mange lesion scores
Live mites were counted in scrapings collected from the edges of active lesions or, if lesions regressed during the study, from the area where active lesions had been present at study commencement. Scrapings were made using a sharp spoon from an area approximately 3 cm × 3 cm. Six sites were scraped on each animal at each occasion. Scrapings were taken on day −1 prior to treatment, on day 7, and at approximately 7-day intervals thereafter until study termination on day 56. For counting the mites, warm water with a small amount of detergent was added to each scraping sample, and the sample was shaken for 10 min. Then the mites were washed out of the samples onto black filter paper by filtering the material through a Buchner funnel apparatus equipped with a vacuum pump. The black filter paper discs were thoroughly examined for living mites (assessed based on motility) using a stereoscopic microscope (Barth and Visser, 1985) . The live mites present in each scraping were counted up to a maximum of 100 in studies 1 and 2; counts above 100 were recorded as ">100". In study 3, all live mites present in a scraping were counted. Total mite counts at each time point were calculated from summing the counts from each scraping site for each animal. The site of each scraping was recorded on a silhouette in addition to the assessment (score) of the mange lesions at each examination. (7) 0 (6)/(+) (2) <0.05 56 + (1)/++ (7) 0 (7)/(+) (1) <0.05 a 0 = healthy skin. (+) = healing lesion, crusts lifted and detached easily but hair growth not complete. + = active lesion, extent less than the palm of the hand. ++ = active lesion, extent more than the palm of the hand. +++ = active lesion, extent more than half of the body of the animal.
b Probability from Wilcoxon rank sum test comparing Eprinomectin ERI to control (ERI vehicle). c Not significant at ˛ = 0.05.
When skin scrapings were taken, the mange lesions were assessed and scored as follows (Rehbein et al., 2003b) : 0 = healthy skin; (+) = healing lesion, crusts detached easily but hair growth not complete; + = active lesion, extent of less than the palm of the hand; ++ = active lesion, extent of more than the palm of the hand; +++ = active lesion, extent of more than half of the body of the animal.
Statistical methods
The number of living mites at each time point was transformed to the natural logarithm of (count + 1) for calculation of geometric means. Treatment groups were compared using Wilcoxon rank sum test at each time point. A two-sided test was used at the 0.05 significance level. Efficacy was calculated as 100[(C − T)/C], where C is the geometric mean for the control (ERI vehicle-treated) group and T is the geometric mean for the Eprinomectin ERI-treated group. Bodyweight and weight gain were analyzed using a mixed model analysis of variance including treatment as a fixed effect and replicate as a random effect. Lesion scores were analyzed using Wilcoxon rank sum test at each time point.
Results
Following infestation, all 44 experimental animals developed active mange lesions spreading from the withers mainly over the shoulder to the chest, the flanks and the back as confirmed by pre-treatment examination. All 22 control (vehicle-treated) animals remained infested with S. scabiei var. bovis, and active lesions were recorded on all of them, throughout the duration of the studies (Tables 2 and 3 ). Mange lesions covering more than half of the body surface were observed in 5 and 7 control animals in studies 1 and 2, respectively. Therefore, those animals received salvage treatments (topical organophosphate spray) for welfare reasons to prevent further spread of mange. After end of the studies, all control animals were appropriately treated with an authorized acaricidal product.
Live mite counts of the Eprinomectin ERI-treated cattle were significantly (p < 0.05) lower than the control (vehicle-treated) cattle counts at all post-treatment study days. Reductions of mite counts were 100% from days 21, 7, and 28 for studies 1, 2, and 3, respectively. Mite counts are summarized in Table 2 .
Mange lesion scores of Eprinomectin ERI-treated cattle at study days 14-56 (study 1), and days 21-56 (studies 2 and 3), were significantly (p < 0.05) lower than the control (vehicle-treated) cattle scores. No "active" lesions were observed on any treated animal from five weeks after treatment onwards to the end of the studies whereas all control (vehicle-treated) cattle had active lesions throughout the study (Table 3) .
Bodyweight and weight gain data are summarized in Table 4 . There was no difference in the weight gain of the animals of the two treatment groups during the pretreatment period (day −58/−56 to day −1). During the eight week observation period following day 0 treatment, cattle treated with Eprinomectin ERI gained more weight than the ERI vehicle-treated controls in all three studies (24.1 kg, 14.2 kg and 4.1 kg, respectively). The difference in final weight and bodyweight gain was significantly different from controls (p < 0.05) in two studies, but not in the third.
With the exception of signs associated with mange infestation, all animals were reported as normal. Hourly observations for four or five hours post-treatment, revealed no changes from pre-treatment health status, indicating that Eprinomectin ERI and ERI vehicle treatments were well accepted. There were no drug-related health problems or adverse drug events observed at any time during the studies.
Discussion
In these studies, a single injection of Eprinomectin ERI effectively eliminated Sarcoptes mites from cattle, and the rapid reduction of mite counts was correlated to the clinical improvement in the treated animals. This efficacy of the Eprinomectin ERI against S. scabiei var. bovis was similar to that previously observed after pour-on application of the 0.5% topical formulation of eprinomectin (Barth et al., 1997; Thompson et al., 1997; Watson and Forbes, 2000; Rehbein et al., 2003a) . These results also are consistent with those of other studies that evaluated the acaricidal activity of the conventional 1% ivermectin and abamectin injectable formulations Sutherland, 1980, 1983; Lavigne and Smith, 1983; Danȇk et al., 1985; Soll et al., 1987; HeinzeMutz et al., 1993; Rehbein et al., 2003b) .
At study completion eight weeks following treatment, there was still some evidence of skin damage at some sites where active mange lesions were present before Eprinomectin ERI treatment. This observation is most likely related to the limited ability of the study animals to groom. In all of the treated animals, skin lesions were scored "healing" from five weeks following treatment.
Eprinomectin ERI treatment of cattle with sarcoptic mange resulted in an improved weight gain compared to the control animals, and this finding re-emphasizes the negative impact of bovine sarcoptic mange on growth performance. This observation is in agreement with numerous studies where significant improvements in weight gain have been reported for cattle which were infested with Sarcoptes mites and successfully treated with eprinomectin pour-on (Barth et al., 1997; Rehbein et al., 2003a) , ivermectin injection or pour-on (Danȇk et al., 1985; Löwenstein and Kutzer, 1996; Rehbein et al., 2003b) , or abamectin injection (Heinze-Mutz et al., 1993) . The higher weight gain responses observed with Eprinomectin ERI-treated cattle in studies 1 and 2 compared to study 3 versus the respective controls are clearly related to the different levels of infestation as demonstrated by the results of examinations of the vehicle-treated controls. Controls in studies 1 and 2 exhibited more severe infestations over the study period than controls in study 3 based on average mite counts and size of active mange lesions. However, therapeutic intervention in sarcoptic mange infested cattle is not only indicated for the clear impact on productivity. Sarcoptic mange was demonstrated to have animal welfare implications, and treatment resulted in reduced levels of behaviors such as rubbing and scratching and longer time spent lying down (Rehbein et al., 2003a) . In addition, there are reports of pruritic dermatoses in humans who became infested with cattle sarcoptic mites when handling infested animals (e.g., Mumcuoglu and Rufli, 1979; Haarløv and Møller-Madsen, 1983 ).
In conclusion, the results of the studies confirmed the excellent efficacy of eprinomectin in an extended-release formulation for treatment of bovine sarcoptic mange at the dose that was selected to provide effective control of nematode infections in cattle for up to 150 days.
